"Vasodilator Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to cause dilation of the blood vessels.
| Descriptor ID |
D014665
|
| MeSH Number(s) |
D27.505.954.411.918
|
| Concept/Terms |
Vasodilator Agents- Vasodilator Agents
- Agents, Vasodilator
- Vasodilators
- Vasorelaxants
- Vasodilator Drugs
- Drugs, Vasodilator
|
Below are MeSH descriptors whose meaning is more general than "Vasodilator Agents".
Below are MeSH descriptors whose meaning is more specific than "Vasodilator Agents".
This graph shows the total number of publications written about "Vasodilator Agents" by people in this website by year, and whether "Vasodilator Agents" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 5 | 10 |
| 1995 | 3 | 8 | 11 |
| 1996 | 14 | 11 | 25 |
| 1997 | 18 | 7 | 25 |
| 1998 | 10 | 9 | 19 |
| 1999 | 12 | 8 | 20 |
| 2000 | 17 | 16 | 33 |
| 2001 | 17 | 15 | 32 |
| 2002 | 18 | 12 | 30 |
| 2003 | 12 | 19 | 31 |
| 2004 | 20 | 9 | 29 |
| 2005 | 16 | 10 | 26 |
| 2006 | 17 | 18 | 35 |
| 2007 | 16 | 18 | 34 |
| 2008 | 12 | 22 | 34 |
| 2009 | 13 | 17 | 30 |
| 2010 | 19 | 13 | 32 |
| 2011 | 9 | 16 | 25 |
| 2012 | 15 | 19 | 34 |
| 2013 | 17 | 21 | 38 |
| 2014 | 9 | 15 | 24 |
| 2015 | 9 | 16 | 25 |
| 2016 | 17 | 12 | 29 |
| 2017 | 9 | 15 | 24 |
| 2018 | 8 | 9 | 17 |
| 2019 | 9 | 10 | 19 |
| 2020 | 6 | 9 | 15 |
| 2021 | 3 | 7 | 10 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 8 | 8 |
| 2024 | 2 | 6 | 8 |
Below are the most recent publications written about "Vasodilator Agents" by people in Profiles.
-
Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation. Cardiovasc Res. 2024 Nov 25; 120(14):1811-1824.
-
Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial. BMC Pediatr. 2024 Nov 01; 24(1):698.
-
Duration of adenosine-induced myocardial hyperaemia: insights from quantitative 13N-ammonia positron emission tomography myocardial perfusion imaging. Eur Heart J Cardiovasc Imaging. 2024 Sep 30; 25(10):1367-1373.
-
Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy. J Drugs Dermatol. 2024 Sep 01; 23(9):725-728.
-
Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease. JACC Heart Fail. 2024 Aug; 12(8):1328-1342.
-
Management of the peri-intubation period in patients with pulmonary arterial hypertension and respiratory failure. Curr Cardiol Rep. 2024 Aug; 26(8):815-820.
-
Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension. Circulation. 2024 Jun 18; 149(25):1949-1959.
-
Milrinone in persistent pulmonary hypertension of newborn: a scoping review. Pediatr Res. 2024 Oct; 96(5):1172-1179.
-
Perioperative sildenafil therapy in pulmonary hypertension associated with congenital cardiac disease: An updated meta-analysis. Asian J Surg. 2024 Jun; 47(6):2551-2557.
-
Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS-986231). Eur J Heart Fail. 2024 Jan; 26(1):142-151.